Previous 10 | Next 10 |
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China PR Newswire Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myelo...
LianBio, a Princeton, NJ-Shanghai biopharma, has filed for a $100 million IPO on the NASDAQ exchange. According to a Bloomberg article, I-Mab is in wide-ranging discussions with US and EU biopharmas for a deal that could out-license an I-Mab asset or involve a direct investment in the...
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting PR Newswire SHANGHAI and GAITHERSBURG, Md. , Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company comm...
I-Mab Announces Upcoming Participation at October Conferences PR Newswire SHANGHAI and GAITHERSBURG, Md. , Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, developme...
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab PR Newswire The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021 The current U.S. NHL clinical tr...
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors PR Newswire SHANGHAI and GAITHERSBURG, Md. , Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nas...
Gainers: Corvus Pharmaceuticals (NASDAQ:CRVS) +73%, Innate Pharma IPHA +51%, SmileDirectClub (NASDAQ:SDC) +12%, Biomerica (NASDAQ:BMRA) +9%, I-Mab (NASDAQ:IMAB) +6%. Losers: Protagonist Therapeutics PTGX -62%, TCR2 Therapeutics TCRR -31%,...
I-Mab Added to FTSE ESG Index Series PR Newswire SHANGHAI and GAITHERSBURG, Md. , Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization...
I-Mab Added to FTSE Russell Global Equity Index Series PR Newswire SHANGHAI and GAITHERSBURG, Md. , Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
Image source: The Motley Fool. I-MAB (NASDAQ: IMAB) Q2 2021 Earnings Call Aug 31, 2021 , 7:00 a.m. ET Jielun Zhu -- Director and Chief Financial Officer Continue reading For further details see: I-MAB (IMAB) Q2 2021 Earnings Call Tran...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...